![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Ofichem Header](https://www.pharmacompass.com/image/flap/ofichem-corp-ad-w31-desktop-headergif-65408.gif)
![Ofichem Header](https://www.pharmacompass.com/image/flap/ofichem-corp-ad-w31-mobile-headergif-45399.gif)
Active Filter(s):
Details:
In this paper, to review the results of both phase III clinical trials, a pooled (post hoc) analysis was performed with patients who met the inclusion criteria for the additional phase III trial
Lead Product(s): Rovatirelin
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 22, 2020